ANVISA Medical Device Regulations: Navigating Low-Risk Changes & Approval Pathways in Brazil
Overview
ANVISA (Agência Nacional de Vigilância Sanitária) is the Brazilian National Health Surveillance Agency responsible for regulating, approving, and monitoring medical devices, pharmaceuticals, and health products across Brazil. Aligned with International Medical Device Regulators Forum (IMDRF) standards, ANVISA classifies medical devices into four risk categories (Class I to IV). Recent regulatory shifts have transitioned Class I low-risk medical devices from traditional cadastro premarket reviews to a streamlined notification pathway, significantly accelerating market entry for compliant global manufacturers
Contact Us
What Is ANVISA and Its Role in Medical Device Regulation?
The National Health Surveillance Agency, widely known as ANVISA (Agência Nacional de Vigilância Sanitária), operates under the Brazilian Ministry of Health to execute sanitary control over products and technologies subject to health surveillance. ANVISA ensures that all health products—including medical equipment, software as a medical device (SaMD), in vitro diagnostics (IVDs), and orthopedic implants—meet strict safety, efficacy, and quality standards before commercial distribution in Latin America’s largest healthcare market.
By executing rigorous controls at ports, borders, and domestic production facilities, ANVISA protects public health while aligning its regulatory framework with global benchmarks like ISO 13485 and IMDRF recommendations.
To explore how Brazil fits into broader international approval workflows, review our guide on centralized global medical device registration strategies.
Regulatory Updates: ANVISA Changes for Low-Risk Medical Devices
To optimize regulatory efficiency and reduce administrative bottlenecks, ANVISA introduced key legislative updates (such as Resolution RDC 751/2022) affecting Class I and Class II low-risk medical devices.
| Regulatory Pathway | Review Process | Key Characteristic |
| Traditional Cadastro Pathway | Full premarket document review by ANVISA prior to market clearance | Required detailed documentation approval before commercial distribution |
| Modern Notification Pathway | Streamlined online declaration filing | Dossier audited primarily during the post-market phase for faster market entry |
From Cadastro to Notification Pathway
Historically, under the cadastro registration route, low-risk device manufacturers were required to submit extensive technical dossiers and legal documentation for premarket evaluation.
Under the updated notification pathway:
Accelerated Time-to-Market: Low-risk Class I devices skip lengthy premarket document reviews, transitioning to an automated or expedited notification processing system.
Audit Preparedness: Manufacturers must still compile and maintain complete technical dossiers, product labeling in Portuguese, and Instructions for Use (IFU) with their designated Brazil Registration Holder (BRH) to pass unannounced ANVISA audits.
Evaluating how recent ANVISA low-risk regulatory shifts affect your product portfolio
Consult Operon Strategist’s global regulatory team today
Step-by-Step Medical Device Registration Process in Brazil
Entering the Brazilian healthcare market through ANVISA requires structured execution across distinct regulatory milestones:
| Step | Action Item |
| 1 | Determine Risk Classification (Class I, II, III, or IV) |
| 2 | Appoint a Licensed Brazil Registration Holder (BRH) |
| 3 | Compile Technical Documentation (Dossier, IFU in Portuguese, Risk File) |
| 4 | Secure ANVISA Good Manufacturing Practices (B-GMP) Certification (Class III/IV) |
| 5 | Submit Electronic Registration / Notification Application via ANVISA Portal |
| 6 | Undergo Technical Evaluation and Pay Regulatory Inspection Fees |
| 7 | Obtain Registration Approval & Execute Post-Market Surveillance Compliance |
1. Risk Classification Determination
Manufacturers must classify their products into Class I (Low Risk), Class II (Low-to-Moderate Risk), Class III (Moderate-to-High Risk), or Class IV (High Risk) based on intended use and duration of contact.
2. Appointment of a Brazil Registration Holder (BRH)
Foreign manufacturers without a physical, licensed presence in Brazil are legally required to appoint a Brazil Registration Holder (BRH). The BRH holds the registration license, liaises directly with ANVISA, and maintains regulatory files.
3. Technical Documentation Preparation
Compile a robust technical dossier containing device descriptions, clinical performance data, risk management files (ISO 14971), Portuguese labeling, and proof of Quality Management System compliance (ISO 13485).
4. Brazilian Good Manufacturing Practices (B-GMP) Certification
For Class III and Class IV devices, ANVISA mandates a physical or audit-based Brazilian Good Manufacturing Practices (B-GMP) inspection. Participation in the Medical Device Single Audit Program (MDSAP) can significantly streamline B-GMP approval timelines.
5. Application Submission & Evaluation
Submit the application through the ANVISA electronic portal. The agency reviews technical submissions, verifies laboratory test reports (such as INMETRO electrical safety certification where applicable), and issues final approval.
6. Post-Market Surveillance
Once registered, manufacturers and BRHs must strictly comply with post-market vigilances, including adverse event reporting, field safety corrective actions, and periodic renewals.
To compare Brazil’s requirements with other major international health authorities, learn how we assist with US FDA 510(k) premarket notifications and EU MDR CE marking compliance.
Strategic ANVISA Regulatory Services Offered by Operon Strategist
Navigating Brazilian medical device approvals requires in-depth knowledge of local health regulations, linguistic compliance, and agency interaction. Operon Strategist provides end-to-end consulting to help medical device and IVD manufacturers successfully enter and scale in the Brazilian market:
ANVISA Device Classification & Pathway Analysis: Mapping product specifications against ANVISA risk rules (RDC 751/2022) to select the correct notification or registration route.
Brazil Registration Holder (BRH) Coordination: Supporting foreign companies in identifying, establishing, and managing compliant BRH representations in Brazil.
Technical Dossier Compilation & Translation: Structuring audit-ready technical files, risk management reviews, and Portuguese IFU documentation in full compliance with ANVISA guidelines.
Turnkey Global Market Expansion: Providing integrated regulatory solutions spanning CDSCO medical device registration in India alongside Latin American, US, and European market approvals.
Need an experienced consultant to prepare your ANVISA technical dossier
Connect with Operon Strategist now
FAQ's
What is ANVISA in Brazilian medical device regulation?
ANVISA (Agência Nacional de Vigilância Sanitária) is Brazil’s health regulatory agency responsible for overseeing the safety, registration, and post-market surveillance of medical devices and pharmaceuticals.
Can a foreign medical device company register directly with ANVISA?
No. Foreign manufacturers must appoint a licensed local entity known as a Brazil Registration Holder (BRH) to submit applications and hold the product registration on their behalf.
What is the validity period of an ANVISA medical device registration?
Full registrations for Class III and Class IV devices are generally valid for 10 years. Class I and Class II notifications do not expire, provided post-market compliance is maintained.
Is B-GMP certification required for all medical device risk classes?
No. Brazilian Good Manufacturing Practice (B-GMP) certification is mandatory primarily for Class III and Class IV high-risk medical devices prior to registration.
Does ANVISA accept MDSAP audit certificates?
Yes. ANVISA recognizes Medical Device Single Audit Program (MDSAP) certificates to satisfy B-GMP requirements, which can eliminate the need for an on-site inspection.